Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Asahi Kasei Buys Arthritis Drug
June 23, 2008
| A version of this story appeared in
Volume 86, Issue 25
Japanese chemical maker Asahi Kasei has bought the Japanese rights to sell pentosan sodium polysulfate for treating osteoarthritis. Launched in 1947 by the German firm Dr. W. Benend as an anticoagulant, pentosan has since been approved for uses including treatment of the bladder ailment interstitial cystitis. The drug is in Phase I clinical trials in Japan as an arthritis treatment. Asahi will undertake development from Phase II trials onward. If pentosan is approved, Asahi will pay undisclosed sums to a Benend affiliate and ReqMed, a small Japanese firm that promotes drug development.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter